Metastatic carcinoid tumor: Changing patterns of care over two decades

Journal of Clinical Gastroenterology

Volumn 44, Issue 3, 2010, Pages 195-199

  Townsend, Amanda ^a   Price, Tim ^b   Yeend, Sue ^a   Pittman, Ken ^a   Patterson, Kevin ^a   Luke, Colin ^c  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c DEPARTMENT OF HEALTH   (Australia)

Author keywords

Carcinoid; Neuroendocrine tumors; Octreotide; Somatostatin analogs; Survival

Indexed keywords

CHROMOGRANIN A; LONG ACTING DRUG; OCTREOTIDE; SOMATOSTATIN;

AGED; ARTICLE; AUSTRALIA; CANCER LOCALIZATION; CANCER STAGING; CARCINOID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOID TUMOR; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; OCTREOTIDE; REGISTRIES; RETROSPECTIVE STUDIES; SOMATOSTATIN; SOUTH AUSTRALIA; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77649334249     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181a9f10a     Document Type: Article

References (21)

1. Yao J, Hasson M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
2. Modlin I, Oberg K, Chung D, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
3. Caplin M, Buscombe J, Hilson A, et al. Carcinoid tumour. Lancet. 1998;352:799-805. (Pubitemid 128717532)
4. Turner G, Johnston B, McCance D, et al. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut. 2006;55:1586-1591.
5. Janson E, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral centre. Ann Oncol. 1997;8:685-690.
6. van der Horst-Schrivers A, Post W, Kema I, et al. Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours. Eur J Cancer. 2007;43:2651-2657.
7. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate longacting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999; 17:600-606.
8. Faiss S, Pape U, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21:2689-2696.
9. Anthony L, Kang T, Shyr Y. Malignant carcinoid syndrome: survival in the octreotide LAR era. J Clin Oncol. 2005;23:4084.
10. Maroun J, Kocha W, Kvols L, et al. Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol. 2006;13:67-76.
11. Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23:4897-4904.
12. Kulke M. Clinical presentation and management of carcinoid tumors. Haematol Oncol Clin N Am. 2007;21:433-455.
13. Stafford S, Coleman R, Gockerman J, et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Cancer. 2004;101:1987-1993.
14. Sarmiento J, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29.
15. Gupta S, Johnson M, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104:1590-1602.
16. Chung M, Pisegna J, Spirt M, et al. Hepatic cytoreduction followed by a novel long-acting somatostatin analog; a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery. 2001;130:954-962.
17. South Australian Cancer Registry 2007 (Data on file).
18. Givi B, Pommier S, Thompson A, et al. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery. 2006;140: 891-897.
19. Moller J, Connolly H, Rubin J, et al. Factors associated with progression of carcinoid heart disease. N Engl J Med. 2003; 348:1005-1015. (Pubitemid 36302245)
20. Arnold R, Mulller H, Schade-Brittinger C, et al. Placebo controlled, double blind, prospective, randomised study of the effect of octreotide LAR in the control of tumour growth in patients with metastatic neuroendocrine midgut tumours: a report from the PROMID study group. Proc GI Symp. 2009;121: Abstract 12.
21. Kvols L, Woltering E. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs. 2006;17:601-608.